Skip to main content
NCBI home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2022;2434:89–102. doi: 10.1007/978-1-0716-2010-6_5

How to Design U1 snRNA Molecules for Splicing Rescue.

Liliana Matos, Juliana I Santos, Mª Francisca Coutinho, Sandra Alves
PMCID: PMC9703209  PMID: 35213011

Abstract

Mutations affecting constitutive splice donor sites (5'ss) are among the most frequent genetic defects that disrupt the normal splicing process. Pre-mRNA splicing requires the correct identification of a number of cis-acting elements in an ordered fashion. By disrupting the complementarity of the 5'ss with the endogenous small nuclear RNA U1 (U1 snRNA), the key component of the spliceosomal U1 ribonucleoprotein, 5'ss mutations may result in exon skipping, intron retention or activation of cryptic splice sites. Engineered modification of the U1 snRNA seemed to be a logical method to overcome the effect of those mutations. In fact, over the last years, a number of in vitro studies on the use of those modified U1 snRNAs to correct a variety of splicing defects have demonstrated the feasibility of this approach. Furthermore, recent reports on its applicability in vivo are adding up to the principle that engineered modification of U1 snRNAs represents a valuable approach and prompting further studies to demonstrate the clinical translatability of this strategy.Here, we outline the design and generation of U1 snRNAs with different degrees of complementarity to mutated 5'ss. Using the HGSNAT gene as an example, we describe the methods for a proper evaluation of their efficacy in vitro, taking advantage of our experience to share a number of tips on how to design U1 snRNA molecules for splicing rescue.

Full text of this article can be found in Bookshelf.

References

  1. van der Feltz C, Anthony K, Brilot A, Pomeranz Krummel DA (2012) Architecture of the spliceosome. Biochemistry 51(16):3321–3333. https://doi.org/10.1021/bi201215r doi: 10.1021/bi201215r. [DOI] [PubMed]
  2. Buratti E, Baralle D (2010) Novel roles of U1 snRNP in alternative splicing regulation. RNA Biol 7(4):412–419 doi: 10.4161/rna.7.4.12153. [DOI] [PubMed]
  3. Carmel I, Tal S, Vig I, Ast G (2004) Comparative analysis detects dependencies among the 5′ splice-site positions. RNA 10(5):828–840. https://doi.org/10.1261/rna.5196404 doi: 10.1261/rna.5196404. [DOI] [PMC free article] [PubMed]
  4. Pinotti M, Bernardi F, Dal Mas A, Pagani F (2011) RNA-based therapeutic approaches for coagulation factor deficiencies. J Thromb Haemost 9(11):2143–2152. https://doi.org/10.1111/j.1538-7836.2011.04481.x doi: 10.1111/j.1538-7836.2011.04481.x. [DOI] [PubMed]
  5. Coutinho MF, Matos L, Santos JI, Alves S (2019) RNA therapeutics: how far have we gone? Adv Exp Med Biol 1157:133–177. https://doi.org/10.1007/978-3-030-19966-1_7 doi: 10.1007/978-3-030-19966-1_7. [DOI] [PubMed]
  6. Hwu WL, Lee YM, Lee NC (2017) Gene therapy with modified U1 small nuclear RNA. Expert Rev Endocrinol Metab 12(3):171–175. https://doi.org/10.1080/17446651.2017.1316191 doi: 10.1080/17446651.2017.1316191. [DOI] [PubMed]
  7. Balestra D, Faella A, Margaritis P, Cavallari N, Pagani F, Bernardi F, Arruda VR, Pinotti M (2014) An engineered U1 small nuclear RNA rescues splicing defective coagulation F7 gene expression in mice. J Thromb Haemost 12(2):177–185. https://doi.org/10.1111/jth.12471 doi: 10.1111/jth.12471. [DOI] [PMC free article] [PubMed]
  8. Lee NC, Lee YM, Chen PW, Byrne BJ, Hwu WL (2016) Mutation-adapted U1 snRNA corrects a splicing error of the dopa decarboxylase gene. Hum Mol Genet 25(23):5142–5147. https://doi.org/10.1093/hmg/ddw323 doi: 10.1093/hmg/ddw323. [DOI] [PubMed]
  9. Lee B, Kim YR, Kim SJ, Goh SH, Kim JH, Oh SK, Baek JI, Kim UK, Lee KY (2019) Modified U1 snRNA and antisense oligonucleotides rescue splice mutations in SLC26A4 that cause hereditary hearing loss. Hum Mutat 40(8):1172–1180. https://doi.org/10.1002/humu.23774 doi: 10.1002/humu.23774. [DOI] [PubMed]
  10. Breuel S, Vorm M, Bräuer AU, Owczarek-Lipska M, Neidhardt J (2019) Combining engineered U1 snRNA and antisense oligonucleotides to improve the treatment of a BBS1 splice site mutation. Mol Ther Nucl Acids 18:123–130. https://doi.org/10.1016/j.omtn.2019.08.014 doi: 10.1016/j.omtn.2019.08.014. [DOI] [PMC free article] [PubMed]
  11. Matos L, Canals I, Dridi L, Choi Y, Prata MJ, Jordan P, Desviat LR, Pérez B, Pshezhetsky AV, Grinberg D, Alves S, Vilageliu L (2014) Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations. Orphanet J Rare Dis 9:180. https://doi.org/10.1186/s13023-014-0180-y doi: 10.1186/s13023-014-0180-y. [DOI] [PMC free article] [PubMed]
  12. Susani L, Pangrazio A, Sobacchi C, Taranta A, Mortier G, Savarirayan R, Villa A, Orchard P, Vezzoni P, Albertini A, Frattini A, Pagani F (2004) TCIRG1-dependent recessive osteopetrosis: mutation analysis, functional identification of the splicing defects, and in vitro rescue by U1 snRNA. Hum Mutat 24(3):225–235. https://doi.org/10.1002/humu.20076 doi: 10.1002/humu.20076. [DOI] [PubMed]
  13. Lund E, Dahlberg JE (1984) True genes for human U1 small nuclear RNA. Copy number, polymorphism, and methylation. J Biol Chem 259(3):2013–2021 [PubMed]

RESOURCES